MS
ELEV

Maven Securities’s Elevation Oncology ELEV Stock Holding History

Maven Securities’s Portfolio ELEV Stock Details ELEV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-16,000
Closed -$204K – 1108
2021
Q2 		$204K Buy
+16,000
New +$198K 0.01% 939

Other funds holding ELEV

ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Maven Securities's ELEV Position: Q3 2021 in Review

Maven Securities sold out of Elevation Oncology (ELEV) in Q3 2021, closing a stake of 16,000 shares — an estimated $204K sold.

Maven Securities first reported a position in ELEV in Q2 2021 and held it in 1 quarter. The position peaked at $204K in Q2 2021. 22 funds tracked by Wall St. Rank hold ELEV as of Q3 2021.

  • Maven Securities reported no remaining Elevation Oncology position as of Q3 2021 after selling out during the quarter.
  • Maven Securities sold 16,000 Elevation Oncology shares in Q3 2021, an estimated $204K.
  • Maven Securities first reported a position in Elevation Oncology in Q2 2021 and held it in 1 quarter.
  • Maven Securities's Elevation Oncology position peaked at $204K in Q2 2021.
  • 22 funds tracked by Wall St. Rank held Elevation Oncology as of Q3 2021.

Based on Maven Securities's 13F filing for Q3 2021, filed 15 Nov 2021.